{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \\< 10\\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.","groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"OG000","title":"Idelalisib+Bendamustine+Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab intravenously (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"OG001","title":"Placebo+Bendamustine+Rituximab"}],"populationDescription":"The study was terminated in agreement with the FDA due to urgent safety measures. Complete data were not collected for any participant.","reportingStatus":"POSTED","timeFrame":"Up to 22 months","title":"Minimal Residual Disease Negativity Rate at Week 36","type":"SECONDARY"}